Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Terminated 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1Head & Neck 1Gynecologic 1Genitourinary 1Gastrointestinal 1Dermatologic 1Breast 1

Conditions

Thyroid Neoplasms 1Skin Neoplasms 1Prostatic Neoplasms 1Pancreatic Neoplasms 1Ovarian Neoplasms 1Neoplasms 1Melanoma 1Lung Neoplasms 1Endometrial Neoplasms 1Colonic Neoplasms 1Carcinoma, Renal Cell 1Carcinoma, Non-Small-Cell Lung 1Breast Neoplasms 1

Interventions

pembrolizumab 26Magnetic Resonance Spectroscopy 14Nivolumab 13Docetaxel 13Specimen Handling 11Radiotherapy 9Paclitaxel 9Radiosurgery 8Early Intervention, Educational 8Cyclophosphamide 8Gemcitabine 7atezolizumab 6Taxes 6Surveys and Questionnaires 6Standard of Care 6Psychiatric Rehabilitation 6Ipilimumab 6Carboplatin 6sargramostim 5Pemetrexed 5Methods 5motexafin gadolinium 4fludarabine 4X-Rays 4Interviews as Topic 4Immunoglobulin G 4Fluorouracil 4Educational Status 4Cisplatin 4Biopsy 4

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Lung Neoplasms × CALAA-01 × Genitourinary × Clear all
NCT00689065 2013-11-01

Safety Study of CALAA-01 to Treat Solid Tumor Cancers

Calando Pharmaceuticals

Phase 1 Terminated
24 enrolled
BreastDermatologicGastrointestinalGenitourinaryGynecologicHead & NeckThoracic

Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Colonic Neoplasms, Lung Neoplasms, Melanoma, Neoplasms, Ovarian Neoplasms, Pancreatic Neoplasms, Prostatic Neoplasms, Skin Neoplasms, Thyroid Neoplasms, Endometrial Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡